Nasdaq

KBC Group: KBC welcomes extension of the KBC Group anchoring agreement made among Cera, KBC Ancora, MRBB and Other Stable Shareholders

Together with MRBB and Other Stable Shareholders, Cera and KBC Ancora have confirmed to extend their anchoring agreement with respect to KBC Group NV for a further term of ten years. In doing so, ...
manilatimes

Cera and KBC Ancora extend their KBC Group 'anchoring agreement'

Cera and KBC Ancora extend their KBC Group 'anchoring agreements' Together with MRBB and the Other Stable Shareholders, Cera and KBC Ancora ensure the shareholder stability and further development of ...
PharmiWeb

FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of ...
Monthly Prescribing Reference

FDA Approves Aflibercept Biosimilar Ahzantive

Comparable efficacy between the biosimilar and reference product was demonstrated in the phase 3 MAGELLAN-AMD study. The Food and Drug Administration (FDA) has approved Ahzantive ® (aflibercept-mrbb), ...
PharmiWeb

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") ...